Fig. 3
From: Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
![Fig. 3](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13045-022-01325-0/MediaObjects/13045_2022_1325_Fig3_HTML.png)
Mode of action of CD161, BTLA, VTCN1, and B7-H3 signaling pathways
From: Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Mode of action of CD161, BTLA, VTCN1, and B7-H3 signaling pathways